PDF(Pubmed)
Abstract：
Chronic inflammation plays a crucial role in carcinogenesis. High levels of serum prostaglandin E2 and tissue overexpression of cyclooxygenase-2 (COX-2) have been described in breast, urinary, colorectal, prostate, and lung cancers as being involved in tumor initiation, promotion, progression, angiogenesis, and immunosuppression. Non-steroidal anti-inflammatory drugs (NSAIDs) are prescribed for several medical conditions to not only decrease pain and fever but also reduce inflammation by inhibiting COX and its product synthesis. To date, significant efforts have been made to better understand and clarify the interplay between cancer development, inflammation, and NSAIDs with a view toward addressing their potential for cancer management. This review provides readers with an overview of the potential use of NSAIDs and selective COX-2 inhibitors for breast cancer treatment, highlighting pre-clinical in vitro and in vivo studies employed to evaluate the efficacy of NSAIDs and their use in combination with other antineoplastic drugs.
摘要：
慢性炎症在癌变中起着至关重要的作用。高水平的血清前列腺素E2和环氧合酶-2（COX-2）的组织过表达已经在乳腺中被描述，泌尿,结直肠,前列腺,肺癌与肿瘤的发生有关，促销,programming,血管生成,和免疫抑制。非甾体抗炎药（NSAIDs）用于多种医疗条件，不仅可以减轻疼痛和发烧，还可以通过抑制COX及其产物合成来减轻炎症。迄今为止,已经做出了巨大的努力来更好地理解和澄清癌症发展之间的相互作用，炎症,和NSAIDs，以期解决它们在癌症管理中的潜力。这篇综述为读者提供了NSAIDs和选择性COX-2抑制剂在乳腺癌治疗中的潜在用途的概述。强调用于评估NSAIDs疗效的临床前体外和体内研究及其与其他抗肿瘤药物的联合使用。
